5/15
05:04 pm
vcyt
Veracyte to Participate in Upcoming Investor Conferences
Low
Report
Veracyte to Participate in Upcoming Investor Conferences
5/13
11:40 am
vcyt
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade [Yahoo! Finance]
5/9
06:44 am
vcyt
Is Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount? [Yahoo! Finance]
Medium
Report
Is Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount? [Yahoo! Finance]
5/8
03:26 pm
vcyt
Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/8
10:26 am
vcyt
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View [Yahoo! Finance]
Low
Report
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View [Yahoo! Finance]
5/8
09:19 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its price target lowered by analysts at Needham & Company LLC from $33.00 to $27.00. They now have a "buy" rating on the stock.
Medium
Report
Veracyte, Inc. (NASDAQ: VCYT) had its price target lowered by analysts at Needham & Company LLC from $33.00 to $27.00. They now have a "buy" rating on the stock.
5/7
04:51 pm
vcyt
Veracyte Announces First Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Veracyte Announces First Quarter 2024 Financial Results [Yahoo! Finance]
5/7
04:05 pm
vcyt
Veracyte Announces First Quarter 2024 Financial Results
Medium
Report
Veracyte Announces First Quarter 2024 Financial Results
5/6
04:22 pm
vcyt
14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding [Yahoo! Finance]
Low
Report
14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding [Yahoo! Finance]
5/6
04:05 pm
vcyt
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
Low
Report
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
4/25
09:19 am
vcyt
PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN [Yahoo! Finance]
Low
Report
PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN [Yahoo! Finance]
4/22
05:00 pm
vcyt
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
Low
Report
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
4/22
08:36 am
vcyt
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance [Yahoo! Finance]
Low
Report
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance [Yahoo! Finance]
4/22
08:30 am
vcyt
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Low
Report
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
4/16
04:08 pm
vcyt
CareDx appoints John Hanna as president and CEO [Seeking Alpha]
Low
Report
CareDx appoints John Hanna as president and CEO [Seeking Alpha]
4/16
09:15 am
vcyt
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 [Yahoo! Finance]
Low
Report
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 [Yahoo! Finance]
4/16
08:30 am
vcyt
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Low
Report
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
4/16
05:59 am
vcyt
Global Precision Medicine Software Markets, 2023-2024 and 2033: Rise in Personalized Healthcare and Cloud-Based Delivery Mode-Based Platforms Elevating Data Accessibility [Yahoo! Finance]
Medium
Report
Global Precision Medicine Software Markets, 2023-2024 and 2033: Rise in Personalized Healthcare and Cloud-Based Delivery Mode-Based Platforms Elevating Data Accessibility [Yahoo! Finance]
4/15
11:05 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Veracyte, Inc. (NASDAQ: VCYT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.
4/2
10:40 am
vcyt
What Makes Veracyte (VCYT) a Lucrative Investment? [Yahoo! Finance]
Low
Report
What Makes Veracyte (VCYT) a Lucrative Investment? [Yahoo! Finance]
2/27
06:02 pm
vcyt
Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines [Yahoo! Finance]
Low
Report
Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines [Yahoo! Finance]
2/27
05:55 pm
vcyt
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Low
Report
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
2/26
11:17 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its price target lowered by analysts at Morgan Stanley from $22.00 to $21.00. They now have an "underweight" rating on the stock.
Low
Report
Veracyte, Inc. (NASDAQ: VCYT) had its price target lowered by analysts at Morgan Stanley from $22.00 to $21.00. They now have an "underweight" rating on the stock.
2/24
08:38 am
vcyt
Veracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
Veracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
2/23
11:41 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Veracyte, Inc. (NASDAQ: VCYT) had its "outperform" rating re-affirmed by analysts at William Blair.